|[October 09, 2013]
Illumina Launches Infinium® HTS-24 Arrays for Unparalleled Content and Sample Throughput Capacity
SAN DIEGO --(Business Wire)--
Illumina, Inc. (NASDAQ:ILMN) today launched an advanced high-throughput
screening (HTS) array format that significantly increases the number of
samples that can be processed on the Infinium® BeadChip family of
genotyping arrays. Illumina's Infinium assay leverages proven
chemistries on a new 24-sample HTS BeadChip that supports up to 750,000
markers per sample and increases scanning capacity by up to three-fold.
"We're excited to introduce this new array format as it enables our
customers to perform larger, more powerful studies that enhance
discovery," said Christian Henry, Senior Vice President and General
Manager, Genomic Solutions at Illumina. "The 24-sample HTS BeadChip
strengthens Illumina's leading position in the array market and further
demonstrates our ability to continue innovation on our array platform,
providing customers with high-quality, high-throughput genotyping
solutions. The new format allows us to offer breakthrough pricing per
sample which is important to enable direct-to-consumer, biobanking,
basic research, and agricultural applications."
Illumina's HumanOmniExpress BeadChip will be the first standard array
available on the 24-sample HTS BeadChip, part of a portfolio of
whole-genome genotyping arrays with new affordable pricing. This
powerful array contains approximately 700,000 markers including the
latest updates from the 1,000 Genomes Project strategically selected to
capture the greatest amount of common SNP variation and drive the
discovery of novel associations with traits and disease. It can also
include up to 50,000 custom markers, making it ideal for those
interested in large genotyping studies such as core labs, genome
centers, and biobanks.
"We are very happy with the quality of data we obtained using the
Illumina Infinium technologies," said Mark Kelleher, Director of
Laboratory Operations at 23andMe. "We are now very excited to deploy the
higher-throughput BeadChips to enhance our ability to process larger
volumes ofsamples as we expand our customer base."
The first consortium-designed array on the 24-sample HTS BeadChip will
leverage the new format and affordable pricing to help researchers
explore the association between variants to five common cancers -
breast, ovarian, colon, lung, and prostate. The Infinium OncoArray-530K
BeadChip (OncoArray), designed in collaboration with leading experts
from the OncoArray consortium and enabled by the development of the
24-sample HTS BeadChip, delivers the core content found on Illumina's
Infinium HumanCore array along with approximately 250,000 additional
candidate variants identified by OncoArray consortium members and room
for 100,000 markers of semi-custom content. The consortium members are
planning a study of unprecedented size which will use the OncoArray to
analyze over 425,000 samples and detect subtle associations within and
between cancer types.
"The OncoArray is a major new tool for providing future insights into
the relationship between genetic variants and cancer predisposition,"
said Doug Easton, Professor of Genetic Epidemiology at Strangeways
Research Laboratory, University of Cambridge, and a leader of the
OncoArray consortium. "It was great working with Illumina to develop the
OncoArray. The array contains the custom content we need, in a
high-throughput format that will make our large-scale study feasible and
should lead to a whole new wave of discoveries."
The HumanOmniExpress BeadChip is now shipping in the 24-sample HTS
format. The OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips
in the 24-sample HTS format are expected to begin shipping in Q1 2014.
For more information, please visit http://www.illumina.com/infiniumHTS.
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected shipping date
for the OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in
the 24-sample HTS format and the planned consortium study. Important
factors that could cause actual results to differ materially from those
in any forward-looking statements include challenges inherent in
developing, manufacturing, and launching new products and services and
the other factors that are detailed in our filings with the Securities
and Exchange Commission, including our most recent filings on Forms 10-K
and 10-Q, or in information disclosed in public conference calls, the
date and time of which are released beforehand. We do not intend to
update any forward-looking statements after the date of this release.
[ Back To TMCnet.com's Homepage ]